Cyclacel Limited

2 trials Commercial sponsor

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

0 Recruiting

2 Completed trials

1 Countries active

2 Unique IMPs

100% Results reported

Phase I/II

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

B-cell lymphoma 2 Hepatocellular carcinoma 2 Breast cancer 2 Non-small cell lung cancer 1 Hormone receptor positive breast cancer 1 Triple negative breast cancer 1 Colorectal cancer metastatic 1 T-cell lymphoma 1 HER2 positive breast cancer 1 Small cell lung cancer 1 Bladder cancer 1 HER2 negative breast cancer 1

Top IMPs

CYC140 MONOHYDROCHLORIDE MONOHYDRATE 1 FADRACICLIB 1

All trials

2 total

A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CYC140, AN ORAL PLK1 INHIBITOR, IN SU… Ended

2024-516290-67-00 Phase I/II 1 country CYC140 MONOHYDROCHLORIDE MONOHYDRATE
A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9… Ended

2024-516289-12-00 Phase I/II 1 country FADRACICLIB

Showing 1–2 of 2 trials

← All sponsors A–Z